HIV Infections Clinical Trial
Official title:
Exercise Effects in HIV-Infected Women
Lipodystrophy is characterized by increased cardiovascular disease. Limited strategies are available to increase cardiovascular fitness in this population, particularly among women. Progressive aerobic and resistance training will increase aerobic capacity and improve strength in HIV positive women with lipodystrophy.
Baseline Testing: Eligible patients will be tested at the General Clinical Research Center
(GCRC) of Massachusetts General Hospital or at the GCRC at Massachusetts Institute of
Technology (MIT). For women with regular menses, the admission will correspond to the early
follicular phase. Patients will receive a menstrual history calendar to submit at the
baseline and 16 week visits. A complete history and physical exam will be performed,
including a detailed history of all drugs being used in the treatment of the HIV disease or
any associated conditions. Weight will be measured and expressed as a percentage of ideal
body weight (IBW) and body mass index. Blood will be sampled to determine hormonal function
(testosterone, free testosterone, SHBG, estradiol, LH, and FSH), nutritional status
(albumin, prealbumin), lipid parameters (HDL, LDL, cholesterol, triglycerides), immune
function (CD4, viral load, CBC), and thrombolytic markers (t-PA, PAI-1). An HIV test will be
performed at the baseline visit only, in order to document patient status. Glucose
homeostasis will be measured with the use of fasting glucose and insulin levels and an oral
glucose tolerance test (OGTT). Heart rate will be monitored to test cardiovascular function.
A spot urine will be collected for bone markers and beta-human chorionic gonadotropin
(bHCG). Lean body mass and fat mass will be determined by a dual energy x-ray absorptiometry
[DEXA] (to be performed at the MIT CRC); total body water will be determined by bioimpedance
analysis; muscle cross-sectional area will be determined by anthropometric measurements. A
quantitative computed tomography (CT) scan of the thigh and abdomen will be done to measure
visceral and subcutaneous fat. A Magnetic Resonance Spectroscopy of calf muscles for
determination of lipid concentrations in skeletal muscle will be done. (Subjects with
contraindications to magnetic resonance imaging [MRI] will be able to remain in the
protocol, but the MR-Spectroscopy will not be performed). A complete dietary assessment and
resting energy expenditure will be performed. Quality of life will be assessed using the MOS
HIV questionnaire and an activity questionnaire as well as the Karnofsky performance
assessment.
A submaximal exercise bicycle test will be done to assess aerobic capability, and a 6 minute
walk test, sit to stand and get up and go tests will be done to assess overall functional
status by the physical therapy (PT) department. Those who are not randomized to exercise at
the baseline visit, will have one repetition maximum (1 RM) testing. The 1 RM is defined as
the maximal amount of weight that can be lifted throughout full range of motion. The 1 RM
will be tested by performing exercises including calf raises, arm curls, lateral raises,
knee flexors, bench press and half squats. The 1 RM testing will be repeated on those who
are not randomized to exercise at the 8 and 16 week visits.
After the baseline investigation is over, subjects will be randomized into one of two groups
(exercise or no exercise) for 16 weeks. Strength training will be performed using standard
free weights under the supervision of a trained physical therapist or member of the study
staff. Each session begins with a 5 minute warm-up and a standard flexibility routine. The
strength training routine will follow and will focus on the following muscle groups: knee
extensors and hip extensors, ankle plantar flexors, elbow flexors, pectoralis and shoulder
abduction. The aerobic training program will follow the general guidelines established by
the American College of Sports Medicine. Training will be performed using a standard
stationery bicycle. Aerobic/endurance exercise will be performed with large muscle groups.
The duration of the aerobic component of the training session will be 20 minutes during the
first two weeks and 30 minutes thereafter. The intensity of the exercise will be 60% of
maximal heart rate during the first two weeks and 75% thereafter. As the weeks progress, the
repetitions and intensity of the exercise will be gradually increased. Subjects return to
the GCRC at 8 weeks for a medical history, a physical exam, weight, and pregnancy test.
Subjects return again at 16 weeks for a visit identical to that at baseline.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |